New item for homologous recombination deficiency testing of patients with ovarian, fallopian tube or peritoneal cancer

This page provides information on the introduction of a new pathology item from 1 January 2024.

Page last updated: 20 December 2023

From 1 January 2024, one new Medicare Benefits Schedule (MBS) item (73307) will be introduced to support homologous recombination deficiency (HRD) testing to determine HRD status (including BRCA1 and BRCA2 status) of tumour tissue in patients with newly diagnosed advanced or metastatic high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

The purpose of the test is to determine eligibility for access to poly-ADP ribose polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme (PBS).

The new MBS item will enable specialists and consultant physicians to request the determination of HRD status (including BRCA1 and BRCA2 status) in patients with newly diagnosed advanced or metastatic high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.

Further information can be found in the Factsheet below.

PDF Version Factsheet - Homologous recombination deficiency testing of patients with ovarian, fallopian tube or peritoneal cancer (PDF 157KB)

Word Version Factsheet - Homologous recombination deficiency testing of patients with ovarian, fallopian tube or peritoneal cancer (Word 131KB)

In this section